Cargando…

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma

Detalles Bibliográficos
Autores principales:	Ladd, Alden, Lilley, Graham, Li, Mingli, Cossette, Dan, Hopkins, Gregory W, Maier, Dawn, Paglia, Michael, Morgan, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646118/ http://dx.doi.org/10.1186/2051-1426-3-S2-P117

Ejemplares similares

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
por: Wong, Sandy W., et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity
por: Garrett, Tracy E, et al.
Publicado: (2015)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
por: Alabanza, Leah M., et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
por: Lin, Regina J., et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
por: Zah, Eugenia, et al.
Publicado: (2020)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
por: Lin, Liang, et al.
Publicado: (2020)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
por: Wang, Ting, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
por: Camviel, Nicolas, et al.
Publicado: (2022)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6sjav56bm6i9udoebqf1v3cbpl